Exelixis, INC 8-K filings

Exelixis stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan and elected 11 directors at the 2026 Annual Meeting.

Exelixis announced strong first quarter 2026 financial results, driven by robust product revenues, and authorized an additional $750 million stock repurchase program.

Exelixis announced preliminary unaudited fiscal year 2025 financial results, provided robust financial guidance for fiscal year 2026, and outlined key strategic priorities and pipeline milestones.

Exelixis, Inc. announced the resignation of its Executive Vice President and General Counsel, Jeffrey Hessekiel, and the promotion of Brenda Hefti to the role.

Exelixis reported strong third-quarter 2025 financial results with significant revenue and EPS growth, raised its full-year financial guidance, and authorized a new $750 million stock repurchase program.

Exelixis, Inc. announced a leadership transition with the appointment of Dr. Dana T. Aftab as EVP, Research and Development, and the departure of Dr. Amy C. Peterson as CMO.

Exelixis announced its second quarter 2025 financial results, reporting $568.3 million in total revenues and $0.65 GAAP diluted EPS, while highlighting positive clinical trial outcomes for zanzalintinib and progress in its early-stage pipeline.

Exelixis, Inc. announced the successful re-election of all 11 director nominees, the ratification of Ernst & Young LLP as its independent auditor, and the advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Exelixis announces impressive first quarter 2025 financial results, driven by CABOMETYX demand, and increases its full-year revenue guidance by $100 million.

Exelixis implements a Special Equity Award Program to incentivize employees and align their interests with shareholder value creation over a five-year period.

Exelixis has authorized a new $500 million stock repurchase program, expected to commence after the completion of the current program in Q2 2025.

Exelixis announces robust fourth quarter and fiscal year 2024 financial results, driven by the strong performance of its cabozantinib franchise, and provides a corporate update highlighting key milestones and future plans.

Exelixis reports strong preliminary FY2024 financial results, offers FY2025 guidance, and highlights key milestones for its cabozantinib franchise and pipeline development.

Exelixis announced strong third-quarter 2024 financial results, driven by robust sales of its cabozantinib franchise, and increased its full-year revenue guidance.

Exelixis secures a favorable court ruling against MSN Pharmaceuticals, upholding the validity of key patents for its cabozantinib product and delaying potential generic competition until 2030.

Exelixis and Merck have entered into a collaboration to evaluate the combination of Exelixis' zanzalintinib with Merck's KEYTRUDA and WELIREG in multiple clinical trials for head and neck and renal cell cancers.

Exelixis announced strong second quarter 2024 financial results, highlighted by a $150 million milestone payment and a new $500 million stock repurchase program.

Exelixis stockholders approved an amendment to the Employee Stock Purchase Plan, increasing the authorized shares by 6 million, and elected 11 directors at their 2024 Annual Meeting.

Exelixis has reached a settlement with Cipla, granting them a license to market generic versions of Cabometyx in the U.S. starting January 1, 2031, and resolving ongoing patent litigation.

Exelixis has initiated a patent infringement lawsuit against Cipla following Cipla's amended application to market generic versions of Cabometyx tablets.

Exelixis announced its first quarter 2024 financial results, reporting total revenues of $425 million and providing updates on its clinical and pipeline development.

Exelixis, Inc. announces that director Jacqueline Wright will not seek re-election at the company's 2024 annual meeting of stockholders.

Exelixis announced positive financial results for the fourth quarter and fiscal year 2023, driven by strong sales of its cabozantinib franchise, and provided updates on its clinical pipeline and corporate strategy.